Storia in 15 fonti

Pharmalittle: We're reading about AstraZeneca-Bristol merger talks, a revised 340B plan, and more

AstraZeneca stock fell as investors balked at reports of merger talks with Bristol Myers Squibb about forming one of the world's biggest drugmakers

Raccontata da

axios.com+3 altre

Confronto fonti

6 prospettive sulla stessa storia

AI · summaries

statnews.comStai leggendo19 h fa

Pharmalittle: We're reading about AstraZeneca-Bristol merger talks, a revised 340B plan, and more

AstraZeneca-BMS merger talks at ~$400B face skepticism (AstraZeneca down 5.5%). Amgen breach via third-party cloud vendor signals rising enterprise risk from managed infrastructure; demands IT governance review of vendor data access and compliance posture.

originale

Timeline cronologica

domenica 2 agosto 2026·endpoints.news
AstraZeneca, Bristol Myers are in talks about merger — report
AstraZeneca & Bristol Myers Squibb in merger talks per Financial Times. AZ worth ~$265B, BMS ~$133B. Deal may involve stock & cash; talks may not lead to deal.
domenica 2 agosto 2026·fortune.com
AstraZeneca said to have explored Bristol Myers merger | Fortune
Bristol Myers Squibb, which has a $133 billion market capitalization, could provide AstraZeneca with a bigger foothold in the US market.

Pharmalittle: We're reading about AstraZeneca-Bristol merger talks, a revised 340B plan, and more

Confronto fonti

Pharmalittle: We're reading about AstraZeneca-Bristol merger talks, a revised 340B plan, and more

Timeline cronologica

AstraZeneca, Bristol Myers are in talks about merger — report

AstraZeneca said to have explored Bristol Myers merger | Fortune

AstraZeneca-Bristol Myers megamerger talk leaves Wall Street wanting more answers

AstraZeneca and Bristol-Myers: when Big Pharma isn’t big enough

Pharma giants AstraZeneca and Bristol-Myers in reported merger talks

AstraZeneca ‘in talks to create £300bn pharmaceutical giant’

AstraZeneca shares fall amid reports of $400bn Bristol Myers Squibb merger talks

An AstraZeneca-Bristol Myers megamerger? Wall Street isn’t thrilled.

Editor’s Corner: Why an AstraZeneca-Bristol Myers Squibb merger is a bad idea

AstraZeneca Held Talks to Combine With Bristol Myers Squibb, FT Says, Citing Sources

AstraZeneca in talks over £300bn mega-merger with US rival – reports

AstraZeneca shares drop 7% after report on $400 billion merger talks with Bristol Myers Squibb

AstraZeneca ‘in talks to create £300bn pharmaceutical giant’

AstraZeneca share prices drop amid £300bn mega-merger talks with US rival

Why Is Bristol-Myers Squibb Stock Surging Monday? - Bristol-Myers Squibb (NYSE:BMY), AstraZeneca (NYSE:AZ

AstraZeneca shares fall amid reports of $400bn Bristol Myers Squibb merger talks

Pharmalittle: We're reading about AstraZeneca-Bristol merger talks, a revised 340B plan, and more

AstraZeneca Stock Nosedives On Mega-Merger Rumor

Pharma giants AstraZeneca and Bristol-Myers in reported merger talks

An AstraZeneca, Bristol Myers Squibb merger could create a cancer-drug giant, but analysts call it 'odd'

AstraZeneca and Bristol-Myers: when Big Pharma isn’t big enough

AstraZeneca-Bristol Myers Merger Buzz Puts Patent Expiration and Deal Economics in Focus - Bristol-Myers

Markets start August on a high with big pharma merger talks grabbing the headlines

AstraZeneca-Bristol Myers megamerger talk leaves Wall Street wanting more answers

UK's AstraZeneca eyeing $400b merger, report says